Sabine Brookman-May: TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR

Sabine Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, posted on X/Twitter:

“Finally out: results of the legacy phase 1b study which built the groundwork for our ongoing phase 2 + 3 studies with the intravesical gemcitabine releasing system TAR-200.

TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR.”